Cannabinoid News and Research

Latest Cannabinoid News and Research

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

e-Therapeutics obtains MHRA approval to recommence recruitment for ETS2101 phase Ia trial

e-Therapeutics plc announces today that it has received approval from MHRA to recommence recruitment of new patients into its ETS2101 phase Ia solid tumours trial being conducted at three centres in the UK.

26 Mar 2014

APS annual meeting to be held in Tampa from April 30 to May 3, 2014

The 33rd Annual Scientific Meeting of the American Pain Society (APS) will convene April 30 through May 3 at the Tampa Convention Center.

7 Mar 2014

New article explores risks associated with using herbal cannabis for rheumatic conditions

Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article published in Arthritis Care & Research, a journal of the American College of Rheumatology, explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy.

3 Mar 2014

Study explores risks associated with using herbal cannabis for treatment of rheumatic conditions

3 Mar 2014

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.

10 Feb 2014

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to standard antiepileptic drugs.

5 Feb 2014

e-Therapeutics temporarily stops phase I trials of ETS2101 due to drug supply issue

e-Therapeutics plc today announces that recruitment of patients into both of the ongoing phase I trials of ETS2101 has been halted temporarily because of a practical issue with stored drug for the trials.

24 Jan 2014

Synthetic cannabinoid molecule created for osteoarthritis

Chemical compounds synthesised in the laboratory, similar to those found in cannabis, could be developed as potential drugs to reduce the pain of osteoarthritis.

7 Jan 2014

e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer

e-Therapeutics plc today announces that the investigator-led phase I trial of ETS2101 in brain cancer will continue into 2014. Five dose escalation steps have been completed without any drug-related serious adverse events and the investigator therefore intends to enrol further patients at higher dose levels.

7 Jan 2014

Molecule produced by brain acts as natural defence mechanism against cannabis

Two INSERM research teams led by Pier Vincenzo Piazza and Giovanni Marsicano (INSERM Unit 862 "Neurocentre Magendie" in Bordeaux) recently discovered that pregnenolone, a molecule produced by the brain, acts as a natural defence mechanism against the harmful effects of cannabis in animals.

3 Jan 2014

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

11 Dec 2013

Stroke may be associated with smoking synthetic marijuana

Add stroke to the list of severe health hazards that may be associated with smoking synthetic marijuana, popularly known as spice or K2, a University of South Florida neurology team reports.

20 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants.

8 Nov 2013

Tel Aviv University researchers find chemicals in marijuana could help treat MS

Multiple sclerosis is an inflammatory disease in which the immune system attacks the nervous system. The result can be a wide range of debilitating motor, physical, and mental problems. No one knows why people get the disease or how to treat it.

8 Oct 2013

Almirall and GKV-SV reach agreement on pricing of Sativex medicine in Germany

...

23 Sep 2013

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

GW Pharmaceuticals plc announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.

18 Sep 2013

Cannabis affects addiction processes in adolescent brain

The nature of the teenage brain makes users of cannabis amongst this population particularly at risk of developing addictive behaviors and suffering other long-term negative effects, according to researchers at the University of Montreal and New York's Icahn School of Medicine at Mount Sinai.

27 Aug 2013

Vanderbilt University scientists discover new approach to treating mood, anxiety disorders

Chemically modified inhibitors of the COX-2 enzyme relieve anxiety behaviors in mice by activating natural "endocannabinoids" without gastrointestinal side effects, Vanderbilt University scientists will report next week.

5 Aug 2013

Cannabinoid News and Research

Latest Cannabinoid News and Research

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

e-Therapeutics obtains MHRA approval to recommence recruitment for ETS2101 phase Ia trial

APS annual meeting to be held in Tampa from April 30 to May 3, 2014

New article explores risks associated with using herbal cannabis for rheumatic conditions

Study explores risks associated with using herbal cannabis for treatment of rheumatic conditions

e-Therapeutics initiates Phase I clinical trial with oral formulation of ETS2101 anti-cancer compound

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

e-Therapeutics temporarily stops phase I trials of ETS2101 due to drug supply issue

Synthetic cannabinoid molecule created for osteoarthritis

e-Therapeutics announces continuation of ETS2101 phase I trial in brain cancer

Molecule produced by brain acts as natural defence mechanism against cannabis

GW Pharmaceuticals receives U.S. patent for treating glioma

Stroke may be associated with smoking synthetic marijuana

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

Tel Aviv University researchers find chemicals in marijuana could help treat MS

Almirall and GKV-SV reach agreement on pricing of Sativex medicine in Germany

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

Cannabis affects addiction processes in adolescent brain

Vanderbilt University scientists discover new approach to treating mood, anxiety disorders

Pittcon Highlights: Cannabis & Psychedelic eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Cannabinoid News and Research

Latest Cannabinoid News and Research

Pittcon Highlights: Cannabis & Psychedelic eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in